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News focus 
Smallpox heads back onto research agenda 

Smallpox was eradicated globally as a disease in the wild almost 30 
years ago but laboratory samples were officially held at two sites. Fears 
that others may also have the virus and concern about bioterrorism 
threats have prompted new research. Michael Gross reports. 
Bill Gates addressed the fifty­
eighth World Health Assembly 
(the highest decision-making 
body of the WHO) in Geneva last 
month, with an outspoken appeal 
to address the major health 
problems of the developing 
countries. “The world is failing 
billions of people,” he said. “We 
act sometimes as if the people 
don’t exist and their suffering isn’t 
happening.” Specifically, he 
pointed to the global health crisis 
caused by malaria, tuberculosis, 
AIDS, and malnutrition, among 
others, highlighting the moral 
obligation of the rich countries to 
use the best of their science and 
technology to address this “tragic 
inequity.” Via the Bill and Melinda 
Gates Foundation, the Microsoft 
founder has in recent years 
emerged as one of the largest 
benefactors for global health 
issues (Curr. Biol. (2003) 13, 
R820). 
With such pressing matters at 
hand and potential future 
problems, such as the avian flu 
strains from Asia, emerging 
rapidly, it might appear strange 
that the global organisation 
should have dedicated a 
significant part of its conference 
time to a disease which has not 
infected anybody in more than a 
quarter of a century. But then, 
smallpox isn’t just any old 
disease. While its eradication at 
the end of the 1970s is undeniably 
the WHO’s greatest triumph, 
smallpox is also one of the most 
infectious deadly diseases in 
humans and one of the oldest 
bioweapons, as its use against 
Native Americans has been 
recorded in 1760. 
These factors, combined with 
the fact that smallpox virus 
samples still exist officially in two 
laboratories (and might exist 
secretly in several other places as 
well), have contributed to the 
smallpox terror attack scare, 
which was fashionable around two 
years ago, when governments 
around the world were frantically 
buying vaccines. Since then, the 
public fear of such an attack and 
the political debates have died 
down a little, but the WHO is left 
holding the baby, namely the 
remaining official smallpox strains. 
The organisation is continuously 
confronted with the thorny 
Bioterrorism threat: Children in Bangladesh more than 30 years ago show symptoms of smallpox infection. There are new calls for 
research on the virus in the wake of bioterrorism fears. (Picture: Science Photo Library.) 
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questions as to what should be 
done with those virus stocks, and 
whether more research with live 
pox viruses should be carried out. 
The recent WHO deliberations 
were triggered by the request of 
US scientists who want to use the 
virus or some of its genes for their 
research, while others call for the 
complete destruction of the 
remaining virus samples. 
Both sides are motivated by the 
fear of smallpox being used in a 
bioterrorist attack. Experts see 
such risks as small compared with 
global health problems, but the 
widespread concerns and fears of 
such an attack, and its potential 
impact have led to detailed 
consideration by governments 
and scientists (Curr. Biol. (2004) 
14, R905). Contingency plans 
have shown that, while localized 
outbreaks could be contained 
with strategically placed 
vaccination programs, a large­
scale attack could easily lead to 
an epidemic, requiring vaccination 
programs for the entire 
population. The classic type of 
vaccine, which achieved the 
eradication of the disease, is 
highly effective but not absolutely 
safe. If all UK citizens were to 
receive this vaccine for example, 
one would have to fear around 
100 casualties. Hence the call for 
continued research into smallpox 
therapies and new vaccines, 
which would require samples of 
the virus to be kept for tests. 
Opponents of this view point to 
the risk that virus samples might 
get stolen out of one of the labs, 
or that the information obtained is 
used to reconstruct or weaponize 
the virus. As in the case of the 
2001 anthrax scare, which was 
later traced back to US 
bioweapons laboratories, the very 
research designed to provide 
protection could in fact end up as 
the source from which attackers 
might get their viral weapons. 
So is it worth keeping the virus 
to fight a small risk which one 
might multiply by this very attempt 
to banish it? The WHO seems to 
think so and has given the virus 
researchers a stay of execution, 
allowing them to continue 
research under tight supervision. 
Under the new set of rules 
prepared by a specialized 
committee and approved by the 
assembly, scientists will be able 
to carry out a limited amount of 
research with pox virus under 
WHO supervision. For example, 
they may express some of its 
genes in less dangerous host 
systems to assess their functions. 
The WHO stated that it “will 
ensure that any research will only 
be conducted after detailed 
proposals have been thoroughly 
examined on a case-by-case 
basis by the WHO Advisory 
Committee on Variola Virus 
Research, paying particular 
attention to biosafety and 
biosecurity issues.” 
At the same meeting, the 
assembly also discussed the 
progress of its ongoing plan to 
establish a strategic stockpile of 
smallpox vaccine in Geneva, 
which would be sent to any part of 
the world that needs it in an 
emergency. In addition to this 
reserve, the organization has 
asked member states to pledge 
additional stocks for international 
emergency use under WHO 
control. Currently, there are 
2.5 million doses held at Geneva, 
and an additional 31 million doses 
have been pledged by member 
countries including the United 
States and France. 
Thus, it would appear that the 
WHO is well-prepared to ensure 
that its dangerous prisoner 
remains locked up and the 
organization and its member 
states can put their resources 
towards eradicating other 
infectious diseases such as polio 
and scaling up the fight against 
those other epidemics that are 
still out there. 
Michael Gross is a science writer in 
residence at the school of 
crystallography, Birkbeck College, 
University of London. He can be 
contacted via his web page at 
www.proseandpassion.com 
Stem cell sirens 
Mediawatch: Bernard Dixon 
looks at the UK reaction to two 
closely related stories. 
Was it a great triumph for the UK 
or a much more significant 
advance by a pioneering team in 
the Far East? Britain’s media were 
unsure and divided on 20 May, 
when they had to handle two 
closely related stories. The first 
was a paper in Science in which 
Woo Suk Hwang and colleagues at 
Seoul National University, South 
Korea, announced a breakthrough 
in producing stem cells from 
cloned human embryos. The 
second was the announcement of 
the first human embryo cloned in 
Britain by Miodrag Stojkovic, 
Alison Murdoch and co-workers at 
the University of Newcastle upon 
Tyne. 
The mid-market newspapers 
highlighted the UK’s achievement. 
‘Giant leap as Britain clones 
human embryo’ ran the headline 
in the Daily Express. ‘Scientists 
clone Britain’s first human 
embryo’ echoed the Daily Mail. 
Both mentioned the Korean work 
too, though the Daily Mail 
relegated this to a shorter story at 
the bottom of the page. BBC 
television and several radio 
channels gave the impression that 
the UK research was the really 
notable happening. 
The greatest contrast with UK 
triumphalism was to be found in 
The Independent, in which 
science editor Steve Connor 
authored a major news-feature 
titled ‘First stem cells taken from 
cloned embryos’, complete with 
an excellent graphic 
representation of the process 
developed in Seoul. This was 
accompanied by a much briefer 
report under a different byline on 
the Newcastle work. The 
Independent reminded readers 
that the Seoul National University 
team reported the world’s first 
cloned human embryo last year, 
and that the UK research was ‘a 
long way behind the Korean 
development’. The newspaper 
also published an editorial (‘There 
is no reason to fear this brave new 
world of hope’) that did not even 
mention the UK research. 
The Financial Times gave the 
headline ‘Asian scientists unveil 
breakthrough in stem cell cloning 
from sick patients’ to its news 
